Success Metrics

Clinical Success Rate
53.3%

Based on 8 completed trials

Completion Rate
53%(8/15)
Active Trials
1(6%)
Results Posted
163%(13 trials)
Terminated
7(41%)

Phase Distribution

Ph not_applicable
1
6%
Ph phase_1
7
41%
Ph phase_2
6
35%
Ph phase_3
1
6%
Ph phase_4
1
6%

Phase Distribution

7

Early Stage

6

Mid Stage

2

Late Stage

Phase Distribution16 total trials
Phase 1Safety & dosage
7(43.8%)
Phase 2Efficacy & side effects
6(37.5%)
Phase 3Large-scale testing
1(6.3%)
Phase 4Post-market surveillance
1(6.3%)
N/ANon-phased studies
1(6.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

8 of 16 finished

Non-Completion Rate

50.0%

8 ended early

Currently Active

1

trials recruiting

Total Trials

17

all time

Status Distribution
Active(1)
Completed(8)
Terminated(8)

Detailed Status

Completed8
Terminated7
Recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
17
Active
1
Success Rate
53.3%
Most Advanced
Phase 4

Trials by Phase

Phase 17 (43.8%)
Phase 26 (37.5%)
Phase 31 (6.3%)
Phase 41 (6.3%)
N/A1 (6.3%)

Trials by Status

recruiting16%
withdrawn16%
terminated741%
completed847%

Recent Activity

1 active trials
Showing 5 of 17
recruitingphase_1

131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)

NCT07015684
completedphase_1

Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome

NCT00047060
withdrawn

Campath-1h Phase I/II Pilot Trial as Immunoablative Therapy for Refractory Systemic Sclerosis

NCT01639573
completedphase_2

Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas

NCT01030900
completedphase_4

CamTac Trial:Campath-Tacrolimus vs IL2R MoAb/Tacrolimus/MMF in Renal Transplantation

NCT00246129
View all 17 trials

Clinical Trials (17)

Showing 17 of 17 trials
NCT07015684Phase 1

131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)

Recruiting
NCT00047060Phase 1

Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome

Completed
NCT01639573

Campath-1h Phase I/II Pilot Trial as Immunoablative Therapy for Refractory Systemic Sclerosis

Withdrawn
NCT01030900Phase 2

Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas

Completed
NCT00246129Phase 4

CamTac Trial:Campath-Tacrolimus vs IL2R MoAb/Tacrolimus/MMF in Renal Transplantation

Completed
NCT00943319Phase 1

Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies

Completed
NCT00416884Phase 2

Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML

Terminated
NCT00683046Phase 2

T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies

Completed
NCT00579111Phase 1

Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)

Terminated
NCT00578903Phase 2

Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia

Terminated
NCT00587847Not Applicable

Campath Maintenance in Chronic Lymphocytic Leukemia

Terminated
NCT00684255Phase 1

Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)

Terminated
NCT00943293Phase 1

Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies

Terminated
NCT00943592Phase 1

Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies

Completed
NCT00462332Phase 2

Fludarabine and Alemtuzumab or Cyclophosphamide Followed by Peripheral Blood Stem Cell Transplant or Alemtuzumab in Treating Patients With Advanced or Progressive Chronic Lymphocytic Leukemia

Completed
NCT00564512Phase 3

Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMP

Completed
NCT00505921Phase 2

Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma

Terminated

All 17 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
17